Alzheimer’s drug gives some patients renewed hope

Geriatrician Michael Woodward says the medical community is excited by the results.

The donanemab study findings were similar to those of its predecessor lecanemab.

"I would regard this as the end of the beginning in Alzheimer's therapies," he said.

"The word breakthrough is used perhaps a little too often, but this is a major breakthrough.